A5006178917- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- interferon and immune responses
- Genetic factors in colorectal cancer
- Economic and Financial Impacts of Cancer
- Viral Infections and Vectors
- PARP inhibition in cancer therapy
- Cholangiocarcinoma and Gallbladder Cancer Studies
- CRISPR and Genetic Engineering
- Medical Imaging Techniques and Applications
- Cancer Genomics and Diagnostics
- 3D Printing in Biomedical Research
- Peptidase Inhibition and Analysis
- Gallbladder and Bile Duct Disorders
- Pediatric Hepatobiliary Diseases and Treatments
- Cancer Mechanisms and Therapy
- Cancer survivorship and care
- Mosquito-borne diseases and control
- Cancer Cells and Metastasis
- Viral Infections and Outbreaks Research
- Viral Infections and Immunology Research
- Frailty in Older Adults
- Lung Cancer Treatments and Mutations
- DNA Repair Mechanisms
- Pancreatic and Hepatic Oncology Research
Servier (Germany)
2022-2024
University of Oxford
2018-2020
CRUK/MRC Oxford Institute for Radiation Oncology
2018-2020
Roche (Switzerland)
2016
Abstract Heterozygous germline mutations in BRCA2 predispose to breast and ovarian cancer. Contrary non-cancerous cells, where deletion causes cell cycle arrest or death, tumors carrying inactivation continue proliferate. Here we set out investigate adaptation loss of focusing on genome-wide transcriptome alterations. Human cells which expression is inhibited for 4 28 days are subjected RNA-seq analyses revealing a biphasic response abrogation. The early, acute consists downregulation genes...
The complexity of the tumor microenvironment is difficult to mimic in vitro, particularly regarding tumor–host interactions. To enable better assessment cancer immunotherapy agents we developed a three-dimensional (3D) heterotypic spheroid model composed cells, fibroblasts, and immune cells. Drug targeting, efficient stimulation cell infiltration, specific elimination or fibroblast areas were demonstrated following treatment with novel immunocytokine (interleukin-2 variant; IgG-IL2v) tumor-...
For decades, treatment of advanced biliary tract cancer (BTC) was confined to the use chemotherapy. In recent years however, number therapeutic options available for patients with unresectable BTC have drastically increased, immunotherapy and targeted gradually joining ranks guideline-recommended regimens.The aim present review is summarise current knowledge on focusing epidemiology, anatomical distribution strategies systemic treatment. We further outline ongoing clinical trials provide an...
Article24 May 2019Open Access Source DataTransparent process Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance Eliana MC Tacconi Genome Stability Tumorigenesis Group, Department of Oncology, The CR-UK/MRC Oxford Institute for Radiation University Oxford, UK Search more papers by this author Sophie Badie Giuliana De Gregoriis Timo Reisländer orcid.org/0000-0003-0981-8311 Xianning Lai Manuela Porru Area Translational Research, IRCCS Regina Elena National...
•First patient-reported HRQoL and post-authorisation efficacy safety data from German mCRC patients receiving FTD/TPI.•Results were consistent with results of pivotal phase III other studies.•FTD/TPI prolonged survival delayed progression manageable toxicity profile.•Treatment FTD/TPI was associated maintained HRQoL. IntroductionTrifluridine/tipiracil (FTD/TPI) improved both overall progression-free (OS, PFS) pre-treated metastatic colorectal cancer (mCRC) in the RECOURSE trial. However,...
Abstract The prospective, multicenter, noninterventional TACTIC study assessed effectiveness and safety of trifluridine/tipiracil (FTD/TPI) in patients with metastatic colorectal cancer (mCRC) a real‐world setting Germany, thus evaluating the external validity findings from pivotal RECOURSE trial. Primary endpoint was overall survival (OS). Secondary objectives included progression‐free (PFS), safety, quality life (QoL). Subgroups comprised good (<3 sites at inclusion, ≥18 months...
Patients with progressing intrahepatic cholangiocarcinoma (iCCA) harboring an isocitrate dehydrogenase 1 (IDH1) mutation who received ivosidenib showed a median progression-free survival (PFS) benefit of 1.3 months compared to placebo in the phase 3 ClarIDHy trial.
In the pivotal phase III RECOURSE trial, trifluridine/tipiracil (FTD/TPI) improved progression-free and overall survival (PFS, OS) of patients with pre-treated metastatic colorectal cancer (mCRC). Subsequently, TALLISUR trial provided post-authorisation efficacy safety data patient-reported outcomes on quality life (QoL) in a German patient cohort. The present analysis reports final efficacy, QoL investigates impact baseline characteristics associated prognostic subgroups outcome.
Trifluridine/tipiracil is approved for the use in later or last-line setting previously treated metastatic colorectal cancer (mCRC) patients who progressed on standard anti-tumor drugs including 5-fluorouracil (5-FU), irinotecan, oxaliplatin, anti-VEGF and anti-EGFR antibodies, are not considered candidates those therapies. In this report, we describe a 67-year-old male patient with <i>KRAS</i>-mutated mCRC metachronous liver lung metastasis failed prior 5-FU-...
Background: QLQ-C30 Global Health Status (GHS) and Eastern Cooperative Oncology Group performance status (ECOG PS) data from PRECONNECT TALLISUR studies were pooled. Materials & methods: Association between changes in ECOG PS GHS patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) was evaluated using Cox regression analysis. Results: 1100 included. There no clinically relevant change baseline score through cycle 7. 63.0% of maintained/improved PS. The...
Trifluridine/tipiracil (FTD/TPI) is approved for use in patients with metastatic colorectal cancer (mCRC) who have progressed on, or cannot tolerate, standard therapies. PRECONNECT was an international, multicentre, open-label, phase IIIb trial, and TALLISUR a prospective, open-label IV trial; both assessed efficacy, safety quality of life (QoL) mCRC receiving FTD/TPI. Here, we present the pooled QoL results from explore whether there association between Eastern Cooperative Oncology Group...
Heterozygous germline mutations in BRCA2 predispose to breast and ovarian cancer. Contrary non-cancerous cells, where deletion causes cell cycle arrest or death, inactivation tumors is associated with uncontrolled proliferation. We set out investigate this conundrum by exploring modalities of adaptation loss focused on genome-wide transcriptome alterations. Human cells which expression was inhibited using a doxycycline (DOX)-inducible shRNA for 4 28 days were subjected RNA-seq analyses. Gene...